Compare CMU & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMU | CNTB |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 128.6M |
| IPO Year | N/A | 2021 |
| Metric | CMU | CNTB |
|---|---|---|
| Price | $3.56 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 82.4K | ★ 105.3K |
| Earning Date | 01-01-0001 | 02-14-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,739.01 |
| P/E Ratio | $47.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.78 | $0.51 |
| 52 Week High | $3.38 | $3.28 |
| Indicator | CMU | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 44.39 |
| Support Level | $3.51 | $2.02 |
| Resistance Level | $3.56 | $2.83 |
| Average True Range (ATR) | 0.03 | 0.20 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 100.00 | 24.51 |
Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.